Inari Medical Inc (NASDAQ: NARI)’s stock price has increased by 0.29 compared to its previous closing price of 79.62. However, the company has seen a 0.31% increase in its stock price over the last five trading sessions. accessnewswire.com reported 2025-02-04 that NEW YORK CITY, NY / ACCESS Newswire / February 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. (“Inari” or “the Company”) (NASDAQ:NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/NARI.
Is It Worth Investing in Inari Medical Inc (NASDAQ: NARI) Right Now?
Company’s 36-month beta value is 1.03.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 13 as “hold,” and 0 as “sell.”
The public float for NARI is 50.51M, and currently, short sellers hold a 4.65% ratio of that floaft. The average trading volume of NARI on February 05, 2025 was 2.18M shares.
NARI’s Market Performance
NARI’s stock has seen a 0.31% increase for the week, with a 54.15% rise in the past month and a 64.98% gain in the past quarter. The volatility ratio for the week is 0.18%, and the volatility levels for the past 30 days are at 2.52% for Inari Medical Inc The simple moving average for the past 20 days is 1.34% for NARI’s stock, with a 57.51% simple moving average for the past 200 days.
Analysts’ Opinion of NARI
Many brokerage firms have already submitted their reports for NARI stocks, with Oppenheimer repeating the rating for NARI by listing it as a “Outperform.” The predicted price for NARI in the upcoming period, according to Oppenheimer is $75 based on the research report published on December 17, 2024 of the previous year 2024.
Stifel, on the other hand, stated in their research note that they expect to see NARI reach a price target of $50. The rating they have provided for NARI stocks is “Hold” according to the report published on September 18th, 2024.
Leerink Partners gave a rating of “Market Perform” to NARI, setting the target price at $47 in the report published on September 03rd of the previous year.
NARI Trading at 26.31% from the 50-Day Moving Average
After a stumble in the market that brought NARI to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 0.11% of gains for the given period.
Volatility was left at 2.52%, however, over the last 30 days, the volatility rate increased by 0.18%, as shares surge +60.44% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +56.66% upper at present.
During the last 5 trading sessions, NARI rose by +0.31%, which changed the moving average for the period of 200-days by +106.33% in comparison to the 20-day moving average, which settled at $78.79. In addition, Inari Medical Inc saw 56.42% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NARI starting from Hoffman William, who sale 200,000 shares at the price of $60.47 back on Jan 06 ’25. After this action, Hoffman William now owns 238,987 shares of Inari Medical Inc, valued at $12,093,174 using the latest closing price.
WILLIAM HOFFMAN, the Director of Inari Medical Inc, proposed sale 200,000 shares at $49.77 during a trade that took place back on Jan 06 ’25, which means that WILLIAM HOFFMAN is holding shares at $9,954,000 based on the most recent closing price.
Stock Fundamentals for NARI
Current profitability levels for the company are sitting at:
- -0.08 for the present operating margin
- 0.86 for the gross margin
The net margin for Inari Medical Inc stands at -0.14. The total capital return value is set at -0.09. Equity return is now at value -17.72, with -12.61 for asset returns.
Based on Inari Medical Inc (NARI), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at 0.43. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is -159.02.
Currently, EBITDA for the company is 15.19 million with net debt to EBITDA at 0.23. When we switch over and look at the enterprise to sales, we see a ratio of 8.13. The receivables turnover for the company is 6.81for trailing twelve months and the total asset turnover is 0.82. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.77.
Conclusion
In a nutshell, Inari Medical Inc (NARI) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
